Replies to post #177328 on Biotech Values

[bladerunner1717]

Yes, AMBI very much on my watch list for potential future consideration. Clearly, the lead value-driver is quizartinib. Although it's in a Phase 3 and you know I hate to bet on Phase 3 binary events, which I usually view as a crapshoot regardless of prior data, I don't think the data is due until at least 2H15. So, there is potential to get in and be able to hold for awhile and hope for a bounce before the pivotal data. Also, they have a pipeline beyond quizartinib, including a drug targeting CSF1R, which I would like to see more data on. Finally, they have a nice cash position to go along with what seems like a cheap valuation

All well and good. But CEO, Martino, hardly inspires confidence after his long stint at Sonus (SNUS). Couldn't AMBI have found somebody better than him? Maybe some others here can comment on Martino and his leadership at SNUS.


Bladerunner

[pcrutch]

Wonder what effect NVS will have on them, Ph3 data in second half of this year on PKC412 in FLT3+ AML. Could present a challenge to AMBI trial enrollment and future sales competition.

http://clinicaltrials.gov/ct2/show/NCT00651261?term=Midostaurin&rank=14

Interesting info. Long road ahead for AMBI - NVS had to screen 3200 patients to get 700 randomized.
http://www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/2013-FEB-11/Capdeville.pdf